番茄社区app

Meeting Coverage >

SGO

Intraperitoneal Carboplatin Boosts PFS in Ovarian Cancer

Should the gynecologic oncology community reconsider IP therapy?

It's Official: Minimally Invasive Hysterectomy Not Safer in Cervical Cancer

Final analysis of LACC trial confirms earlier findings

Lenvatinib Packaging for Endometrial Cancer Tied to $168 Million in Overspending

Presenter breaks news at SGO that drug developer commits to overhauling dose reduction program

Selinexor Proves Mettle in Advanced or Recurrent Endometrial Cancer

Benefit was greatest among patients with wild-type p53 cancer in SIENDO trial

Novel ADC Promising in Tough-to-Treat Ovarian Cancer

Ocular AEs an issue with mirvetuximab in folate receptor alpha-high platinum-resistant disease

Add-on Pembrolizumab Tied to Good QoL in Women With Advanced Cervical Cancer

PRO-based analysis of KEYNOTE-826 trial shows favorable benefit-risk ratio

Adjuvant Chemo Disappoints in Low-Grade Serous Ovarian Cancer

Study suggests no improvement in overall survival

Triage System Gets High Marks for Ovarian Cancer Debulking Surgery

Key factors predicted threefold higher risk of 90-day mortality with primary surgery

HIPEC Combo Doubles PFS in Advanced Ovarian Cancer

Cisplatin/paclitaxel boosts outcomes without increasing complications in registry study

Combo Tx Active in Recurrent, Platinum-Resistant Ovarian Cancer

Ixabepilone plus bevacizumab yielded responses in a third of patients

Little Benefit With Adjuvant Therapy for High-Risk Endometrial Cancer

Chemo prevented relapse but did not improve survival, no benefit from radiotherapy

Androgen Receptor Inhibitor Active in Endometrial Cancer

SGO: Apatinib for platinum-resistant ovarian cancer, pembrolizumab for advanced vulvar cancer

Hormonal IUD Shows Promise in Early Endometrial Cancer

Regression seen in 82% of women with precancerous lesions

Small Molecule Inhibitor Shows Promise in Resistant Ovarian Cancer

Responses in 37% of patients with AVB-500, higher without prior bevacizumab

Is MIS Viable for Interval Debulking in Ovarian Cancer?

Retrospective study compared approach versus open surgery after neoadjuvant chemotherapy

PARP Inhibitor Tops Chemo for Recurrent BRCA Ovarian Cancer

Modest improvement in PFS with rucaparib but worse outcome for reversion mutation

Practice-Changing Trial in Second-Line Endometrial Cancer

Pembrolizumab plus lenvatinib improved median OS by nearly 7 months versus chemotherapy

Avelumab Flops Again in Ovarian Cancer

Another negative phase III trial, now in the first-line setting

PARP Inhibitors Still Work in HRD-Low Ovarian Cancer

In VELIA, homologous recombination deficiency score prognostic but not predictive

KRAS May Predict Benefit of MEK Inhibitors in Some Ovarian Cancers

Nearly 7-month PFS boost in patients with KRAS mutations

Add-On Metformin No Help in Advanced Endometrial Cancer

Trial highlights deep racial disparities in treatment response, survival outcomes

Herceptin Boosts OS in HER2-Positive Uterine Cancer

New data bolster targeted approach for aggressive tumor type

Post-Op HPV Vaccine Cuts Cervical Precancer Recurrences

Plus osteoporosis in gynecologic cancer survivors, and a novel approach to CIN2/3

Potential Game Changer for Endometrial Cancer

A 30% response rate in recurrent/advanced disease, 49% in MSI-H tumors

Early Data Send Strong Signal in Advanced Gyn Cancers

Clinical benefit rate tops 90% in pair of single-center studies

'End of the Road' for Trabectedin in Ovarian Cancer?

Trial stopped for futility, but 13-month OS improvement seen in patients with BRCA mutations

When PARP Inhibitors Fail in Ovarian Cancer

Study identifies subgroup for whom another go could be worthwhile

Avelumab Combo Falls Short in Advanced Ovarian Ca

But showed promise in PD-L1-positive group

PARP Inhibitor Benefit Gets a TWiST in Recurrent Ovarian Ca

Analysis attempts to quantify patients' quality of survival

Studies Seek Role for Anti-PD-1 Drugs in Gyn Cancers

Activity in resistant ovarian, mutated endometrial cancers

Unexpected Outcome in Hysterectomy Study

More cancer recurrences, worse survival with minimally invasive surgery

Women Do Well Without Opioids after Gyn Surgery

An 89% drop in opioid use with restrictive prescribing protocol

Gyn Cancer Research Gets Short Shrift in Funding

Mortality-adjusted analysis shows huge disparity versus other cancers

HPV-Targeted Drug Sets Survival Mark in Cervical Cancer

Highest-ever 12-month survival in recurrent, metastatic disease

Survival Bump in IVB Cervical Cancer with Pelvic RT

Improved OS, PFS in retrospective analysis

Anti-PARP Tx Works in Advanced Ovarian Cancer

TAMPA, Fla. -- Advanced ovarian cancer treated with PARP inhibitor maintenance therapy had significant improvement in progression-free survival, extending beyond first progression, investigators reported.

Cancer Ascites Responds to Outpatient Tx

TAMPA, Fla. -- Outpatient treatment of malignant ascites with a monoclonal antibody proved safe and feasible and led to a survival benefit in gynecologic cancer patients who could receive chemotherapy, a small clinical study showed.

Extreme Obesity Adds More Risk in Hysterectomy

AUSTIN, Texas -- Increasingly severe obesity drives up complication rates after hysterectomy, and outcomes continually worsen with rising body mass index, according to results from a study reported here.

SGO: Low Cancer Risk with Septated Ovarian Tumors

SAN FRANCISCO -- Septated ovarian tumors have a low risk of malignancy and can be followed safely with ultrasound, data from a large prospective cohort study showed.